Professor Guido Kroemer stands as a preeminent cell biologist whose transformative research has fundamentally reshaped our understanding of cellular death mechanisms and their implications for cancer therapy. Born in Leer, Germany on June 11, 1961, he completed his medical training at the University of Innsbruck in Austria before earning his doctorate in Molecular Biology from the Autonomous University of Madrid. Currently holding professorships at Université Paris Cité and serving as Director of the Metabolomics and Cellular Biology Platforms at Gustave Roussy Cancer Campus, he also leads the Inserm research team focused on Metabolism, Cancer, and Immunity. His distinguished career includes founding directorship of the European Research Institute for Cancer and Immunology and significant leadership roles at the Cordeliers Research Centre, where he serves as Deputy Director.
Kroemer's pioneering discoveries regarding mitochondrial control in programmed cell death have revolutionized the field, with his identification of mitochondrial membrane permeabilization as a decisive step in the cell death process representing a landmark contribution to cellular biology. His extensive research portfolio encompasses the anti-aging properties of autophagy and the critical immune responses that determine the efficacy of cancer treatments, providing foundational insights that have guided therapeutic development for decades. With more than 1,700 scientific publications, including 72 featured in premier journals such as Cell, Nature, and Science, his scholarly impact is extraordinary as evidenced by over 460,000 citations in Google Scholar. This remarkable citation record firmly establishes Kroemer among the most influential biomedical researchers of the contemporary era, whose work continues to shape experimental approaches and clinical strategies worldwide.
As Editor in Chief of Cell Stress, Microbial Cell, MedComm Oncology, and Seminars in Immunology, Professor Kroemer has significantly influenced scientific discourse while mentoring generations of researchers who now lead laboratories across the globe. His leadership extends to directing major research initiatives, including the Equipex Onco Pheno Screen platform and the EATI research group, which integrate cutting edge technologies to advance our understanding of cancer metabolism and immunity. Recognized as a Highly Cited Researcher by Web of Science in 2019, his sustained scholarly impact is further reflected in his membership across numerous prestigious academies, including EMBO, Leopoldina, and the European Academy of Sciences. Professor Kroemer continues to pioneer research at the intersection of fundamental cell biology and clinical oncology, driving innovation that promises to transform cancer treatment paradigms and improve patient outcomes on a global scale.
